Patents Assigned to Relinia, Inc.
  • Patent number: 11530247
    Abstract: This invention provides for a fusion protein between a single chain TNFR2 Selective Agonist protein (scTNFR2 Selective Agonist) and a dimerization domain, such as an IgGFc protein. The single chain TNFR2 Selective Agonist moiety provides a therapeutic activity by selectively activating the TNFR2 form of the TNF-? receptor, thus selectively stimulating Tregs and/or increasing myelin deposition.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: December 20, 2022
    Assignee: RELINIA, INC.
    Inventors: David C Foster, Lutz B Giebel, Leonard G Presta
  • Publication number: 20200369739
    Abstract: This invention provides for a fusion protein between a single chain TNFR2 Selective Agonist protein (scTNFR2 Selective Agonist) and a dimerization domain, such as an IgGFc protein. The single chain TNFR2 Selective Agonist moiety provides a therapeutic activity by selectively activating the TNFR2 form of the TNF-? receptor, thus selectively stimulating Tregs and/or increasing myelin deposition.
    Type: Application
    Filed: June 5, 2018
    Publication date: November 26, 2020
    Applicant: Relinia, Inc.
    Inventors: David C Foster, Lutz B Giebel, Leonard G Presta